JBC INTERFERin siRNA transfection reagent

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Evans, D. R. H.
Right arrow Articles by Hemmings, B. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Evans, D. R. H.
Right arrow Articles by Hemmings, B. A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 274, Issue 34, 24038-24046, August 20, 1999


Functional Expression of Human PP2Ac in Yeast Permits the Identification of Novel C-terminal and Dominant-negative Mutant Forms*

David R. H. Evans, Timothy Myles, Jan Hofsteenge, and Brian A. HemmingsDagger

From the Friedrich Miescher Institute, Maulbeerstrasse 66, CH-4058 Basel, Switzerland

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The protein phosphatase 2A (PP2A) holoenzyme is structurally conserved among eukaryotes. This reflects a conservation of function in vivo because the human catalytic subunit (PP2Ac) functionally replaced the endogenous PP2Ac of Saccharomyces cerevisiae and bound the yeast regulatory PR65/A subunit (Tpd3p) forming a dimer. Yeast was employed as a novel system for mutagenesis and functional analysis of human PP2Ac, revealing that the invariant C-terminal leucine residue, a site of regulatory methylation, is apparently dispensable for protein function. However, truncated forms of human PP2Ac lacking larger portions of the C terminus exerted a dominant interfering effect, as did several mutant forms containing a substitution mutation. Computer modeling of PP2Ac structure revealed that interfering amino acid substitutions clustered to the active site, and consistently, the PP2Ac-L199P mutant protein was catalytically impaired despite binding Tpd3p. Thus, interfering forms of PP2Ac titrate regulatory subunits and/or substrates into non-productive complexes and will serve as useful tools for studying PP2A function in mammalian cells. The transgenic approach employed here, involving a simple screen for interfering mutants, may be applicable generally to the analysis of structure-function relationships within protein phosphatases and other conserved proteins and demonstrates further the utility of yeast for analyzing gene function.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Protein phosphatase 2A (PP2A)1 is a ubiquitous eukaryotic enzyme that is highly conserved between species (1, 2) and a member of the PPP family of protein Ser/Thr phosphatases that includes PP1 and calcineurin (3). PP2A is implicated in diverse cellular processes (4) and coordinates signal transduction through direct, regulatory interaction with protein kinases (5, 6). PP2A exists as a holoenzyme in which the catalytic subunit (PP2Ac) binds a regulatory PR65/A subunit to form a core dimer, which associates with a large number of variable B subunits encoded by at least three gene families (7-11). Regulatory subunits of PP2A influence its substrate specificity and intracellular targeting (12-14), and enzyme activity is modulated further by post-translational modification of the PP2Ac C terminus (4).

The budding yeast Saccharomyces cerevisiae possesses two proteins Pph21p and Pph22p similar to mammalian PP2Ac (15). The homologous PPH21 and PPH22 genes encoding yeast PP2Ac are functionally redundant because either can be deleted without effect. However, doubly deleting PPH21 and PPH22 causes severe growth inhibition and is lethal in the absence of PPH3, encoding a distantly related protein phosphatase that provides overlapping function (16). Conservation of PP2A extends to the holoenzyme because the S. cerevisiae Tpd3p (17), Cdc55p (18), and Rts1p (19) are similar to the regulatory PR65/A, PR55/B, and PR61/B' subunits, respectively, of mammalian PP2A, and Tpd3p and Cdc55p bind Pph21p/Pph22p in vivo (20). This suggests that PP2A regulation is conserved between species, and consistent with this, a novel methyltransferase that targets the PP2Ac C-terminal leucine residue and modulates PP2A activity (21) is present in both higher eukaryotes and yeast (22, 23).

The role of PP2A has been studied biochemically, through the use of inhibitors and viral tumor antigens that target the enzyme specifically, and genetically, via inactivating subunit mutations. Moreover, the crystal structure of the PR65/A subunit of PP2A was recently solved (24). Together these studies have implicated PP2A in processes including cell cycle regulation, cellular morphogenesis, protein synthesis, and viral replication (4). Although the biochemical and functional properties of PP2A differ from those of protein phosphatase type 1 (PP1), the catalytic subunits of these enzymes share ~46% amino acid sequence identity. The crystal structure of PP1gamma 1 has been solved (25, 26) and provides a framework for predicting the role of specific PP2Ac residues and interpreting the effect of changes generated by mutagenesis. In this study, we have functionally expressed human PP2Ac in S. cerevisiae and used this as a convenient system to generate novel mutations in human PP2Ac and analyze their effect on PP2A function in vivo. We have identified a number of novel, interfering mutant forms of PP2Ac and rationalized their effects using a model of PP2Ac structure based on that of PP1gamma 1.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Strains, Media, Plasmids, and Sequence Analysis-- Yeast strains are described in Table I. Rich (yeast peptone medium, YPD), minimal (synthetic dextrose, SD), and 5-FOA media were described (27). Plasmids pBluescript II (pBS; Stratagene), pYES2 (Invitrogen), pYPGE2 (28), pASZ11 (29), pRS314, pRS316, YEp351, YEp352, YCpDE1, and YCpAS6 (30) were described. DNA constructs were sequenced with dRhodamine dye terminators using Perkin-Elmer GeneAmp PCR system 2400, 9700 thermocycler and analyzed using an Applied Biosystems PRISM 377 sequencer. Pairwise alignment of human PP2Acalpha and yeast Pph22p was performed using ALIGN (Baylor College of Medicine).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Saccharomyces cerevisiae strains used in this study

Manipulation and Analysis of Human PP2Acalpha cDNA-- Two forms of HsPP2Ac tagged with the HA epitope were used. A single HA tag was inserted downstream of the PP2Acalpha initiation codon, by amplifying the human cDNA (31) in the PCR using an appropriate forward primer. A SalI/KpnI HA-PP2Acalpha clone, or a frameshifted allele, HA-PP2Acalpha -FS lacking the second nucleotide of the ninth codon, was introduced between the PGK1 promoter/CYC1 terminator of vector pYPGE2 generating plasmids YEpDE-PGK-Calpha and YEpDE-PGK-FS. A similar NcoI/BamHI fragment was introduced into vector pACTII (P. Legrain, Pasteur Institute) fusing the HA-PP2Acalpha ORF to the Gal4 activation domain. A second sequence encoding an extended HA-PP2Acalpha ORF was used for HsPP2Ac immunoprecipitation experiments because it encodes native HsPP2Ac with an epitope accessible to the 12CA5 antibody (32). PP2Acalpha containing this tag was introduced into vectors pYPGE2 (YEpDE-PGK-CHA) and pYES2 (YEpDE2-Calpha HA), and similarly tagged PP2Ac-2512 and PP2Ac-118 alleles were introduced into pYES2 (YEpDE-GAL-2512HA and YEpDE-GAL-118HA). Mutations were generated in HA-PP2Acalpha by PCR amplification using QuickChange (Stratagene). Truncations of the HA-PP2Acalpha ORF were generated in vitro by PCR using a reverse primer that introduced a stop at codon 309 (PP2Ac-Delta 309), 301 (PP2Ac-Delta 300), or 67 (PP2Ac-Delta 67) (codon numbering for untagged PP2Acalpha ). PP2Acalpha mutant alleles were inserted between the HindIII/BamHI sites of pYES2 and downstream of SalI in pYPGE2. Plasmid DNA was prepared from strain DEY1-Calpha using a Kristal extraction kit (Cambridge Molecular Technologies); six plasmids, recovered from independent ampr Escherichia coli colonies, were tested for a restriction pattern (SalI/KpnI or XbaI) identical to that of YEpDE-PGK-Calpha . The nucleotide sequence of one plasmid was analyzed, and it encoded YEpDE-PGK-Calpha .

Preparation of Yeast Cell Extracts and Western Blot Analysis-- Cell extracts were prepared as described (33). Protein transfer and Western blotting were as described (9). Antibodies were diluted in TNPT (1.0% Nonidet P-40, 0.3% Triton X-100 in Tris-buffered saline (TBS, 150 mM NaCl, 50 mM Tris-HCl, pH 7.5)) containing 7.5% powdered milk. Membranes were washed with TNPT. Detection was by goat anti-mouse IgG-HRP and ECL (Amersham Pharmacia Biotech).

Construction of the pph22Delta 52 Allele and myc-TPD3 Alleles-- The PPH22 gene was PCR-amplified using a forward primer appropriate to generate pph22Delta 52 encoding an initiation codon followed by codons 53-377 of PPH22 and a stop codon TAA. A pph22Delta 52 1.0-kb SalI/KpnI fragment was fused to the PGK1 promoter in pYPGE2. A 3.4-kb genomic fragment encompassing the yeast TPD3 gene (17) was inserted into YEp351 (YEpDE11) and was template for a PCR generating a TPD3 ORF, flanked by its native promoter/terminator, with a double c-myc tag downstream of the initiator codon (myc-TPD3). A 3169-base pair myc-TPD3 SacI/SalI fragment was inserted into vectors pRS314, YEp351, and YEp352 (YCpDE3-2m, YEpDE3-2m, and YEpDE4-2m, respectively). The myc-TPD3 allele is functional because YCpDE3-2m rescued the ts growth defect of haploid tpd3Delta 1::URA3 mutant cells (not shown).

Immunoprecipitations and Protein Phosphatase Activity Measurements-- To precipitate HA-tagged proteins, PAS CL-4B (Amersham Pharmacia Biotech) equilibrated in 1× TBS was incubated at 4 °C with 12CA5 overnight and then washed extensively (six times with 10 volumes of TBS). Antibody-saturated beads (PAS-12CA5, 35 µl) were added to ~100 µl of yeast extract, incubated at 4 °C for 2 h, and washed extensively. Phosphatase assays (50 µl) were performed on immune complexes according to Promega (kit V2460) measuring phosphate release over 10 min from a chemically synthesized phosphopeptide (RRA(pT)VA, where pT indicates phosphothreonine) with MnCl2 present at 1 mM. Assays were performed in duplicate on immune complexes prepared independently, and activity is expressed as units (1 unit = 1 µmol of phosphate hydrolyzed per min). For co-immunoprecipitations, cell extracts were prepared in Buffer A (100 mM Tris-HCl pH 7.5, 200 mM NaCl, 1.0 mM EDTA, pH 8.0, 0.5 mM dithiothreitol, 0.1% Nonidet P-40) with protease inhibitors. PAS-12CA5 (35 µl) was added to 1.0 mg of extract, incubated at 4 °C for 2-5 h, washed extensively with Buffer A, and boiled in 50 µl of Laemmli Buffer.

Generation of PP2Acalpha Dominant-negative Alleles-- A 970-base pair HindIII/BamHI HA-PP2Acalpha fragment was inserted into the GAL1/CYC1 promoter/terminator cassette of pYES2, and this plasmid, YEpDE-Calpha HA, was cleaved with AflII/BstEII generating a gap within the PP2Acalpha ORF. In parallel, the intact insert in YEpDECalpha HA was amplified under mutagenic conditions for the PCR (0.2 ng/µl template DNA, 1× reaction buffer (Perkin-Elmer), 0.5 pmol/µl primer T7, 0.5 pmol/µl primer 20622 (5'-AGAGGATCCTTACAGGAAGTAGTCTGGGGTACGACGAGTAAC), 0.5 mM each dCTP and dTTP, 0.1 mM each dATP and dGTP, 3 mM MgCl2, 0.1 or 0.2 mM MnCl2, 5 units of Taq polymerase, 33 cycles of 94 °C for 1.5 min, 55 °C for 2.0 min, 72 °C for 3.0 min). PP2Acalpha mutant alleles were recovered by co-transforming (34) cells (strain DEY1-Calpha ) with gapped plasmid DNA (0.5 µg) and mutagenic PCR product (200 ng). Ura+ transformants were selected on SD lacking uracil and then replica-plated to synthetic dextrose (SD) and synthetic galactose (SG) medium to identify plasmids containing dominant-negative alleles expressed from the GAL1 promoter. Plasmids recovered from cells capable of growth on glucose but not galactose were checked for gap repair by restriction analysis and reintroduced into DEY1-Calpha to confirm growth inhibition on galactose. To test competition between PP2Acalpha wild type and mutant alleles, the 2.3-kb SnaBI/EcoRI fragment from YEpDE-Calpha HA, containing HA-PP2ACalpha fused to the GAL1 promoter, was inserted between the SmaI/EcoRI sites of vector pASZ11[CEN.ARS ADE2] and named YCpDE11-GAL-Calpha . The HA-PP2Acalpha -FS allele was similarly inserted into pASZ11 (YCpDE11-GAL-FS) as a negative control for PP2Acalpha function. To express PP2Ac-2512 from the GAL1 promoter in pASZ11 the 0.75-kb NcoI/SacI fragment of YCpDE11-GAL-Calpha was replaced by the equivalent DNA from YEpDE-GAL-2512 (PP2Ac-2512 in pYES2) and tested (plasmid YCpDE11-GAL-2512) for inducible growth inhibition in DEY1-Calpha as above.

Galactose-induced Expression of PP2Acalpha in Cells Grown in Liquid Medium-- PP2Acalpha wild type and mutant alleles were expressed from the GAL1 promoter of pYES2 in yeast strain INVSC1. Cells were grown to a density of 5.0 × 106 per ml at 30 °C in selective (synthetic raffinose, SR) medium containing raffinose (2.0%), glycerol (3.0%), and casamino acids (0.2%) followed by the addition of an equal volume of SG medium containing galactose at 4.0%.

Modeling of PP2Ac Structure-- A homology-based model was obtained using the coordinates of PP1gamma 1 (a gift from Dr. David Barford, University of Oxford). Residues 1-309 of human PP2Acalpha and 8-316 of human PP1gamma 1 were aligned using "GAP" (GCG Wisconsin Package, Madison, WI). The optimal alignment (46% identity with four 1-amino acid gaps) was used by "MODELER" (Ref. 35; BIOSYM/Molecular Simulations, San Diego, CA) to build and refine five PP2Ac models. PP1gamma 1 appears unstructured between residues 299 and 316 (25), and no models were obtained for PP2Ac in this region (the C terminus of the models is Pro-291). The best model, selected on the basis of the lowest violations of the probability density functions, was evaluated using "Profiles-3D" (Ref. 36; BIOSYM/Molecular Simulations, San Diego, CA). Its overall self-compatibility score, 139.2, was close to that expected for a polypeptide chain of this length, 140.6, indicating reliability of the model.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Functional Replacement of Yeast PP2Ac by Human PP2Ac-- The primary structure of PP2Ac is highly conserved from yeast to humans (2); excluding an N-terminal extension (~50 residues) to the S. cerevisiae protein, the yeast and human PP2Ac polypeptides display 71% amino acid sequence identity. To investigate whether the conservation of PP2Ac structure reflects a conservation of function, we tested the ability of human PP2Ac (HsPP2Ac) to functionally replace the corresponding protein from S. cerevisiae (ScPP2Ac). We used haploid yeast cells (strain DEY1) triply deleted for the chromosomal PPH21, PPH22, and PPH3 genes and supported by a plasmid-borne PPH22 gene encoding ScPP2Ac (30). A second plasmid, carrying the human PP2Acalpha clone fused to the yeast PGK promoter and the hemagglutinin epitope, was introduced, and heterologous expression of HA-tagged HsPP2Ac was analyzed by immunoblot analysis (see Fig. 1A). Two forms of HsPP2Ac were detected, suggesting that the human protein undergoes post-translational modification in yeast, and both forms migrated at approximately 36 kDa, faster than the endogenous ScPP2Ac at 43 kDa (not shown). HsPP2Ac was analyzed for function in yeast using a plasmid shuffling assay, testing for the ability of cells to grow in the absence of ScPP2Ac (Fig. 1B); this assay tests for the ability of yeast cells to grow on medium containing 5-FOA (37) which negatively selects against the essential URA3 PPH22 plasmid encoding ScPP2Ac in strain DEY1. Cells containing PP2Acalpha lost PPH22 at high frequency and grew on 5-FOA medium, whereas cells containing a non-functional PP2Acalpha clone with a 5'-frameshift (PP2Acalpha -FS) or the empty vector failed to grow without PPH22. An incoming TRP1 PPH22 plasmid also substituted for the resident URA3 PPH22 plasmid as expected. This indicates that HsPP2Ac is functional in yeast and that it supports cell growth in the absence of ScPP2Ac. Consistent with this, cells cured of PPH22 by plasmid shuffling contained plasmid DNA carrying the PP2Acalpha clone (see "Experimental Procedures") and expressed the 36-kDa HsPP2Ac (Fig. 1A). Moreover, in an alternative test of function (Fig. 1C), PP2Acalpha rescued the ts growth defect of pph22-172 mutant yeast cells that undergo loss of endogenous ScPP2Ac function at 37 °C because of a conditional-lethal point mutation in PPH22 (30). In addition, a truncated allele of PPH22 lacking the first 52 codons (pph22Delta 52) functionally replaced full-length PPH22 in strain DEY1 (Fig. 1D) even at 37 °C (not shown) indicating that the N-terminal extension to ScPP2Ac is dispensable for cell viability, consistent with the ability of HsPP2Ac to replace the endogenous yeast enzyme.


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 1.   Functional expression of human PP2Ac in yeast. A, Western blot analysis of HA-tagged HsPP2Ac. Yeast cell extracts (10 µg) were resolved by SDS-PAGE and probed with 12CA5 monoclonal antibody. Lane 1, strain DEY1-P2 (expressing untagged ScPP2Ac); lane 2, strain DEY1-Calpha (expressing HA-tagged HsPP2Ac). Molecular mass marker shown on the right. B, functional replacement of ScPP2Ac (Pph22p) by HsPP2Ac via plasmid shuffling. TRP1 plasmids carrying human PP2Acalpha (YEpDE-PGK-Calpha ), the frameshifted allele PP2Acalpha -FS (YEpDE-PGK-Calpha FS), no insert (vector pYPGE2), or yeast PPH22 (YCpDE1) were introduced into strain DEY1, and cells were grown to saturation (5 × 107 cells/ml) in liquid SD with uracil. Cell suspensions (5 µl) were diluted (1:1, 1:10, or 1:100), spotted onto agar medium containing (5-FOA) or lacking (SD + uracil) 5-fluoroorotic acid, and incubated at 30 °C for 3 days. C, suppression of the pph22-172 ts mutant growth defect by PP2Acalpha . Cells of strain DEY107 containing PP2Acalpha (YEpDE-PGK-Calpha ) vector (pYPGE2) or PPH22 (YCpDE1) were grown to saturation in selective SD, and cells (5 µl, diluted 1:1 or 1:10) were spotted onto YPD agar and incubated at 37 °C or 24 °C for 36 h. D, functional replacement of wild type PPH22 by the pph22Delta 52 allele. Cells (strain DEY1) containing either pph22Delta 52 (YEpDE-PGK-Delta 52) vector (pYPGE2) or PP2Acalpha (YEpDE-PGK-Calpha ) were grown to saturation in SD with uracil and spotted onto 5-FOA as described in B. pph22Delta 52 cells (strain DEY1-Delta 52) obtained on 5-FOA displayed wild type growth at 37 °C (not shown).

HsPP2Ac Binds the Yeast PR65/A Subunit, Tpd3p-- Because PP2Ac heterodimerizes with a regulatory PR65/A subunit (1), we tested whether HsPP2Ac binds the endogenous yeast PR65/A subunit Tpd3p in vivo. We tagged Tpd3p with the Myc epitope (Myc-Tpd3p) and asked whether it co-precipitates with HA-tagged HsPP2Ac from a yeast extract (Fig. 2A). When proteins were precipitated using the 12CA5 antibody, Myc-Tpd3p but not untagged Tpd3p was detected in an immune complex prepared from cells expressing HA-HsPP2Ac, whereas Myc-Tpd3 was absent from a similar complex prepared from cells expressing ScPP2Ac lacking the HA epitope. This indicates HsPP2Ac binds the yeast PR65/A subunit and that, consistently, HsPP2Ac interacted with Tpd3p in the yeast two-hybrid system (Fig. 2B). This supports the conclusion that HsPP2Ac is functional in yeast. Moreover, HsPP2Ac prepared from yeast was catalytically active (see below).


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 2.   HsPP2Ac binds the endogenous yeast regulatory PR65/A subunit, Tpd3p. A, the Myc-tagged Tpd3p co-precipitates with HA-tagged HsPP2Ac. Yeast extracts were prepared from cells expressing HA-HsPP2Ac and Myc-Tpd3p (strain DEY1-c42m), HA-HsPP2Ac and untagged Tpd3p (DEY1-c352), or untagged ScPP2Ac and Myc-Tpd3p (DEY11-42m) as indicated, and HA-tagged proteins were precipitated with the 12CA5 monoclonal. Following SDS-PAGE and Western transfer, cell extracts and immune complexes were probed with 12CA5 to detect HA-HsPP2Ac (~36 kDa) or with the 9E10 monoclonal to detect Myc-Tpd3p (~73 kDa). Molecular mass markers are shown on the right. B, HsPP2Ac interacts with Tpd3p in the yeast two-hybrid system. TPD3 fused to GAL4DB in vector pAS1-CYH2 (a gift from Mike Stark, Dundee University) and PP2Acalpha fused to GAL4AD in vector pACTII (see "Experimental Procedures") were introduced into strain Y166 separately or together as indicated and tested for activation of the GAL1::URA3 reporter gene; cell suspensions (5 µl) were diluted (1:1 or 1:10), spotted onto SD lacking uracil, and incubated at 30 °C for 3 days. A similar pattern of activation of the Y166 GAL1::lacZ reporter was observed (not shown).

Interfering Mutant Forms of HsPP2Ac-- We used yeast cells functionally expressing HsPP2Ac to identify mutant forms of the human enzyme that interfere with wild type PP2Ac function. A library of human PP2Acalpha mutant alleles, fused to the yeast GAL1 promoter, was generated by random mutagenesis and screened for those that inducibly inhibited cell growth on galactose medium. Eleven mutant alleles were identified (Fig. 3) that dominantly inhibited the growth of cells expressing wild type PP2Acalpha constitutively from the PGK1 promoter (strain DEY1-Calpha ). The PP2Ac-2512 allele inhibited growth even when transferred to an alternative GAL plasmid (see "Experimental Procedures") demonstrating that its dominant-negative effect was caused by mutation of PP2Acalpha and not vector DNA (not shown). Five mutant alleles contained nonsense mutations within the PP2Acalpha ORF and encoded C-terminally truncated forms of HsPP2Ac. Of these, the PP2Ac-182 allele encoded the largest truncation deleting the C-terminal 145 amino acids. A further dominant-negative allele, PP2Ac-144-2, encoded a -1 frameshift mutation within codon 307 of PP2Acalpha , extending the ORF by 57 codons. Together this indicates that an intact C terminus is required for wild type HsPP2Ac function, and its modification may cause an interfering effect. However, the PP2Ac-Delta 67 allele, encoding HsPP2Ac lacking residues 68-309 (Fig. 3), did not cause a dominant-negative effect (see "Discussion"). Another five PP2Acalpha mutant alleles encoded missense mutations, and in each case (excepting PP2Ac-2446) a single amino acid substitution was sufficient for dominant inhibition of cell growth (Fig. 3). Immunoblot analysis of HA-tagged HsPP2Ac proteins revealed that wild type PP2Acalpha and dominant-negative missense alleles were expressed from the GAL1 promoter to a similar level, whereas nonsense alleles were expressed to a lower level (data not shown). Because GAL-expressed wild type PP2Acalpha did not inhibit cell growth, the interfering effect of PP2Acalpha dominant-negative alleles must be caused by an intrinsic property of their products and not by toxic, high levels of expression.


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 3.   PP2Acalpha mutant alleles causing dominant inhibition of yeast cell growth. Left, the ORF of wild type PP2Acalpha and mutant alleles generated in vivo (see "Experimental Procedures") or in vitro by subcloning or site-directed mutagenesis. s, position of substitution mutation (hatched box) frameshift and 57-codon extension to the PP2Acalpha ORF encoded by CYC1 vector sequences caused by deletion of the nucleotide corresponding to T922 in the untagged PP2Acalpha ORF. Center, allele names and identity of encoded mutation(s). Substitutions are according to residue number in untagged HsPP2Ac. Substitutions encoded downstream of a premature stop codon are in parentheses. Right, inducible inhibition of yeast cell growth. Transformant cells (strain DEY1-Calpha ) expressing a PP2Acalpha wild type or mutant allele from the inducible GAL1 promoter were grown to saturation in selective SD. Approximately 100 cells were spread onto glucose (non-inducing) and galactose (inducing) agar medium and incubated at 22 °C for up to 7 days. -, no colonies visible by eye; +/-, microcolonies; +, ++, +++, colonies of approximately 1.0, 1.5, and 2.0 mm diameter, respectively.

PP2Acalpha Mutant Alleles Inhibit PPH22 and pph22-12 Cell Growth-- The screen for PP2Acalpha dominant-negative alleles was performed in yeast cells containing human, and lacking yeast, PP2Ac. To test for growth inhibition in the presence of ScPP2Ac, we introduced PP2Acalpha mutant alleles into PPH22 pph21Delta pph3Delta cells, in which Pph22p provides ScPP2Ac function. When expressed from the GAL1 promoter, each PP2Acalpha dominant-negative allele tested inhibited cell growth (Table II) suggesting that its product interfered with ScPP2Ac function. Moreover, when PP2Acalpha dominant-negative alleles were expressed in pph22-12 pph21Delta pph3Delta cells, containing a mutant Pph22p functionally impaired by a single amino acid substitution but which nevertheless display wild type growth at 30 °C (30), the PP2Acalpha mutant alleles inhibited growth at 30 °C, and this inhibition was more severe than that observed in wild type (PPH22) cells (Table II). Thus, dominant-negative alleles of PP2Acalpha display an allele-specific interaction with PPH22 and pph22-12 causing severe growth inhibition when endogenous ScPP2Ac is functionally impaired. These results support the notion that PP2Ac function is conserved between species and that inhibitory mutant forms of HsPP2Ac interfere with endogenous PP2Ac, whether HsPP2Ac or ScPP2Ac.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Dominant-negative effect of PP2Acalpha mutant alleles on wild-type (PPH22) and pph22-12 mutant yeast cell growth
PP2Ac alleles (described in Fig. 3) were expressed from the inducible GAL1 promoter in vector pYES2. Transformed yeast cells were grown to saturation in SD liquid medium and spread (~100 cells) onto SD (Glu) and SG (Gal) agar medium and incubated at 30 °C for the length of time indicated.

Predicted Effect of Dominant-negative Mutations on PP2Ac Structure-- To gain insight into the interfering effect of PP2Acalpha dominant-negative mutations, we built a model of HsPP2Ac structure based on the crystal structure of PP1gamma 1 (25). The overall structure of the PP2Ac model (residues 1-291) is strikingly similar to that of PP1gamma 1 (Fig. 4) with an architecture of 10 alpha -helices and 3 beta -sheets. PP1gamma 1 possesses a shallow substrate-binding site, with a di-nuclear metal ion center at the catalytic site. In agreement with the observation that PP2A is a divalent cation-dependent enzyme (1), the predicted HsPP2Ac metal ligands Asp-57, His-59, Asp-85, Asn-117, His-167, and His-241 (equivalent to Asp-64, His-66, Asp-92, Asn-124, His-173, and His-248 in PP1gamma 1) are positioned correctly to bind the two metal ions. Moreover, HsPP2Ac contains the substrate-binding residues Arg-89, Asn-117, His-118, Arg-214, and Tyr-265 and the auxiliary residue Asp-88 (which may form a catalytically important salt bridge with His-118) equivalent to Arg-96, Asn-124, His-125, Arg-221, Tyr-272, and Asp-95 of PP1cgamma . The longest truncation of HsP2Ac (Cys-165stop, encoded by PP2Ac-182) deletes two metal ligands, one substrate-binding residue and a major portion of the active site, and is likely to be catalytically inactive. Surprisingly, the secondary structural elements missing from this truncated protein do not form an independent domain but comprise a subdomain (alpha 7, alpha 8, beta -sheet 3 (beta 7-beta 9), and alpha 9) and part of beta -sheet 2 (beta 6, beta 10, beta 12, beta 11) and beta -sheet 1 (beta 13, beta 14). Even the shortest truncation (Tyr-218stop, PP2Ac-216) similarly lacks beta 9 and alpha 9 in the subdomain and part of both beta -sheets 1 and 2. Presumably the remainder of the polypeptide in these and the other HsPP2Ac truncation mutants folds sufficiently to form a subdomain, comprising alpha 1, beta 4, beta 3, beta 2, and alpha 4-alpha 6, that binds PP2A-interacting proteins and thereby promotes an interfering effect.


View larger version (125K):
[in this window]
[in a new window]
 
Fig. 4.   Computer model of PP2Ac structure. The alpha -helices are shown as blue cylinders; beta -sheets as green arrows; metal ions as purple spheres. The position of amino acids substituted in this study and the location of truncations causing an interfering effect are shown as red spheres and red arrows, respectively.

Five PP2Acalpha dominant-negative alleles encoded missense mutations, and the interfering effect of four of these could be rationalized as they encode substitutions disturbing the PP2Ac active site and thus may impair catalytic activity. The Y127N substitution (PP2Ac-153-1 allele) changes a highly conserved tyrosine residue (equivalent to Tyr-134 of PP1gamma 1) that interacts with the Ser(P)/Thr(P) substrate and whose side chain is in van der Waals contact with His-118 and Asp-88. Like in PP1gamma 1, His-118 is predicted to serve as a general acid in the PP2Ac active site, protonating the Ser(P)/Thr(P) leaving group and accelerating the phosphatase reaction, whereas Asp-88 may enhance the acidic character of His-118. The F150I substitution (PP2Ac-225-1) changes a conserved residue (Phe-156 in PP1gamma 1) which is distant from the active site but forms a hydrogen bond with the buried Glu-119 residue; Glu-119 is adjacent to His-118 and is in van der Waals contact with the metal-binding residue Asp-85. Thus, the F150I substitution may affect the orientation of the Glu-119 side chain and alter metal ligation, although interestingly, an alternative aromatic residue tyrosine (PP2Ac-2446-2 allele) is tolerated at this position. The conserved Leu-199 residue (Leu-205 in PP1gamma 1) occurs at the C terminus of helix alpha 8 and its main chain carbonyl group hydrogen-bonds with the side chains of Asn-117, His-167, and His-241 which are metal ligands. Disruption of local structure by L199P (PP2Ac-2512) could affect metal binding, abolish contact with Cys-196, and alter the orientation of Trp-200 that has been proposed to contact substrate residues flanking Ser(P)/Thr(P). Finally, the T258P substitution (PP2Ac-136) changes a highly conserved, penultimate residue of beta 12 (Thr-265 in PP1gamma 1) which forms part of beta -sheet 2 (beta 1, beta 5, beta 6, beta 10, beta 12, and beta 11). The polypeptide chain emerging from beta 10 packs on top of this beta -sheet and contains the His-241 metal ligand. Furthermore, the gamma -methyl group of Thr-258 packs against its main chain. Thus, a proline at position 258 could interfere with metal binding by His-241. The fifth dominant-negative missense mutation encoding V159E (PP2Ac-153-2) is more difficult to rationalize in terms of a catalytically impaired PP2Ac. However, Val-159 (Val-165 in PP1gamma 1) is part of the hydrophobic core located between beta -sheets 1 and 2. Introducing a negatively charged glutamate into it could, although distant from the active site, have a global effect on active site structure and catalysis.

The PP2Ac C-terminal Leucine Residue Is Dispensable for Function-- Because truncated forms of HsPP2Ac cause an interfering effect, we explored the functional role of the highly conserved PP2Ac C terminus. Deleting the HsPP2Ac C-terminal nine amino acids (PP2Ac-Delta 300 allele) caused an inhibitory effect that was less severe than that caused by larger truncations (Fig. 3), whereas deleting the C-terminal Leu-309 residue alone (PP2Ac-Delta 309) caused no interfering effect (not shown). The C-terminal leucine residue is invariant among PP2Ac enzymes, and so we tested whether it is essential for HsPP2Ac function (Fig. 5). Remarkably, the PP2Ac-Delta 309 allele functionally replaced the yeast PPH22 gene encoding ScPP2Ac in strain DEY1, as did PP2Ac-A309 encoding HsPP2Ac-L309A with alanine at position 309, indicating that Leu-309 is dispensable for HsPP2Ac function in vivo. In contrast, the PP2Ac-Delta 300 allele failed to replace PPH22 (Fig. 5) indicating that a largely intact C terminus is essential. Surprisingly, PP2Ac-Delta 309 supported a rate of yeast cell growth that was higher (doubling time (td) 3.1 ± 0.49 h in liquid YPD at 30 °C, strain DEY1-Delta 309) than that supported by PP2Ac-A309 (td 4.6 ± 0.84 h, strain DEY1-A309) and was similar to that supported by wild type PP2Acalpha (td 2.8 ± 0.28 h, strain DEY11) (see "Discussion").


View larger version (49K):
[in this window]
[in a new window]
 
Fig. 5.   Functional analysis of PP2Acalpha truncation mutants by plasmid shuffling. Cells (strain DEY1) expressing the PP2Ac-Delta 309, PP2Ac-A309, or PP2Ac-Delta 300 mutant allele or wild type PP2Acalpha from the PGK1 promoter, or the empty pYPGE2 vector, were incubated on 5-FOA and monitored for growth as described in Fig. 1B.

PP2Ac-L199P Is Catalytically Impaired but Binds Tpd3p-- To explore the mechanism by which HsPP2Ac mutant proteins containing a substitution mutation may interfere with wild type PP2Ac function, we tested the PP2Ac-L199P protein (PP2Ac-2512 allele) for catalytic activity in vitro (Fig. 6A). Unlike wild type HsPP2Ac recovered from yeast, PP2Ac-L199P displayed no detectable okadaic acid-sensitive phosphatase (PP2A) activity greater than the vector control. This is consistent with the prediction from molecular modeling that the L199P substitution inhibits PP2Ac activity by disrupting binding and/or metal ion-mediated hydrolysis of the substrate and suggests that catalytic impairment of PP2Ac-L199P may contribute to its interfering effect in vivo. To test this we analyzed an active site mutant of HsPP2Ac2 mutated for the His-118 residue of PP2Ac, which may serve as a general acid in the active site of PP2Ac protonating the Ser(P)/Thr(P)-leaving group. This mutant HsPP2Ac possesses a neutral asparagine residue in place of His-118 which is predicted to dramatically reduce Vmax for the phosphatase reaction (25). Unlike wild type HsPP2Ac, PP2Ac-H118N displayed no detectable PP2A activity in vitro (Fig. 6B) supporting the prediction that His-118 is important for HsPP2Ac catalytic function. Moreover, when the PP2Ac-118 allele encoding PP2Ac-H118N was expressed from the yeast GAL1 promoter, it caused an inhibition of cell growth similar to that caused by PP2Acalpha dominant-negative missense alleles (see Fig. 3). This indicates that catalytic impairment of HsPP2Ac may cause an interfering effect. Finally, we asked whether PP2Ac-L199P binds the yeast Tpd3p PR65/A subunit in vivo. When HA-tagged proteins were precipitated from yeast extracts, the Myc-tagged, but not untagged, Tpd3p was detected in complexes containing wild type HA-HsPP2Ac and HA-PP2Ac-L199P but not in complexes lacking HA-tagged PP2Ac protein (Fig. 6C). Thus, like wild type HsPP2Ac, PP2Ac-L199P binds the endogenous yeast PR65/A subunit suggesting that, although catalytically impaired, it folds sufficiently to bind PP2A-interacting proteins thereby contributing to its interfering effect on PP2Ac function.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 6.   Characterization of the human PP2Ac-L199P mutant protein. A, PP2Ac-L199P is catalytically impaired. Phosphatase activity was measured in immune complexes prepared from yeast containing wild type HA-HsPP2Ac (wt), HA-PP2Ac-L199P (L199P), or no HA-tagged protein (-). B, an active site mutant of HsPP2Ac is catalytically impaired. PP2A activity was measured in immune complexes containing HA-HsPP2Ac (wt) or HA-PP2Ac-H118N (H118N) and corrected for activity present in the absence of HA-tagged protein (-). HA-tagged forms of HsPP2Ac were inducibly expressed from the yeast GAL1 promoter of vector pYES2 in cells grown in liquid galactose medium (see "Experimental Procedures") for 15 h. Cells containing empty vector served as a negative control (-). HA-tagged proteins, precipitated by the 12CA5 monoclonal antibody from 200 µg (A) or 100 µg (B) of yeast cell extract, were assayed for phosphatase activity in the absence (open bars) or presence (closed bars) of 10 nM okadaic acid to identify PP2A activity directed against a phosphopeptide substrate. Numbers represent the mean values (±S.D.) from four (A) or three (B) experiments. The inset to A and B shows a representative Western blot analysis of immune complexes prepared in parallel with those used for phosphatase assays; HA-tagged C subunits (C) were present in the relevant complexes at similar levels and were absent from the (vector) control. Immunoglobulin heavy and light chains were detected above and below PP2Ac. C, the Myc-tagged Tpd3p co-precipitates with HA-PP2Ac-L199P. Extracts were prepared from cells expressing HA-HsPP2Ac and Myc-Tpd3p (strain DEN2-3m) or untagged Tpd3p (DEN2-11), HA-PP2Ac-L199P, and Myc-Tpd3p (DEN2512-3m), or untagged Tpd3p (DEN2512-11), Myc-Tpd3p alone (DEY23m), or untagged Tpd3p alone (DEY211) as indicated below the blot. HA-tagged proteins were precipitated with 12CA5, and resolved cell extracts and immunoprecipitates were probed with 12CA5 or 9E10 monoclonal to detect HA-tagged PP2Ac (~36 kDa) and Myc-Tpd3p (~73 kDa) respectively. Molecular mass markers are shown on the right.

Competition in Vivo between Wild Type and Mutant Forms of HsPP2Ac-- To probe further the mechanism by which interfering forms of HsPP2Ac inhibit cell growth, we tested for reversal of growth inhibition by overexpression of wild type HsPP2Ac. PP2Acalpha was expressed from the GAL1 promoter in yeast cells co-expressing a GAL-driven dominant-negative allele, and PP2A function was assessed by colony formation (Table III). With one exception (PP2Ac-316) growth inhibition caused by PP2Acalpha missense alleles was alleviated by co-overexpression of wild type PP2Acalpha , as was inhibition caused by PP2Ac-144-2, encoding the aberrant C-terminal extension to HsPP2Ac. In contrast, a 5'-frameshifted PP2Acalpha mutant clone failed to reverse the growth inhibitory effect of the dominant-negative alleles, as expected. This suggests that a competition occurs in vivo between wild type and substituted mutant forms of HsPP2Ac. Nevertheless, increased expression of PP2Acalpha failed to reverse the growth inhibition caused by C-terminally truncated forms of PP2Ac suggesting that these inhibit wild type HsPP2Ac function by a different, non-competitive mechanism.

                              
View this table:
[in this window]
[in a new window]
 
Table III
Competition between human PP2Acalpha wild type and dominant-negative alleles expressed in yeast from the GAL1 promoter
Yeast cells (strain DEY1-Calpha ) contained a resident wt PP2Acalpha allele expressed at low level from the constitutive PGK1 promoter (PGK-PP2Acalpha ) and a resident dominant-negative allele (GAL-PP2Ac-n) expressed from the inducible GAL1 promoter of vector pYES2. A wt (GAL-PP2Acalpha ) or non-functional, frame-shifted allele (GAL-PP2Acalpha -FS) was introduced and expressed from the GAL1 promoter of vector YCpDE11-GAL-Calpha and YCpDE11-GAL-FS, respectively. Transformant cells (~100) were spread on SD (Glu) or SG (Gal) agar medium and incubated at 22 °C for 7 days.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

PP2A Is Functionally Conserved between Species-- The amino acid sequence of PP2Ac is highly conserved between species, and budding yeast contains an endogenous phosphatase activity with biochemical characteristics remarkably similar to those of mammalian PP2A (33). We have shown by genetic and biochemical criteria that HsPP2Ac functionally replaces the endogenous PP2Ac of S. cerevisiae demonstrating that the evolutionary conservation of PP2Ac structure and enzyme activity reflects a conservation of function in vivo. In accordance with this, HsPP2Ac bound the endogenous yeast regulatory PR65/A subunit consistent with the observation that the most highly conserved residues in PR65/A localize to a continuous ridge extending along one face of the molecule. This ridge presents an exposed hydrophobic surface predicted to contact the PP2A catalytic and other subunits in the holoenzyme complex (24). Indeed, a mammalian regulatory B'alpha subunit of PP2A functionally replaces its homologue (Rts1p) in S. cerevisiae (38) indicating that the conservation of PP2A function extends to the holoenzyme.

Inhibitory Mechanism of HsPP2Ac Interfering Mutant Proteins-- Yeast cells in our screen for PP2Acalpha dominant-negative alleles were kept alive by wild type PP2Acalpha expressed at low level from the constitutive PGK1 promoter, and to inhibit cell growth, dominant-negative alleles were inducibly expressed from the GAL1 promoter to a level approximately 10-fold higher (not shown). Thus the dominant-negative effect of PP2Acalpha mutant alleles requires their expression to a higher level than wild type PP2Acalpha , and indeed, PP2Acalpha mutant alleles expressed from the PGK1 promoter did not inhibit cell growth (data not shown). Moreover, during competition experiments involving simultaneous overexpression of a PP2Acalpha wild type and dominant-negative allele, the growth inhibition caused by missense alleles was generally reversed by increased expression of wild type PP2Acalpha , although inhibition caused by nonsense alleles was not. This suggests that HsPP2Ac proteins containing substitutions compete with wild type HsPP2Ac in vivo by titrating PP2A regulatory subunits and/or substrates, whereas truncated forms of HsPP2Ac (and PP2Ac-T258P) may sequester PP2A subunits and/or substrates irreversibly. Consistent with this we found that, like wild type HsPP2Ac, the PP2Ac-L199P mutant protein bound the endogenous yeast PR65/A subunit suggesting that it causes an interfering effect by titrating PR65/A into a non-functional complex. Because the core dimer serves as an essential scaffold for the recruitment of B-type regulatory subunits, PP2Ac-L199P may effectively titrate other subunits, interfering with targeting and/or substrate specificity of the wild type enzyme. We found that PP2Ac-L199P is catalytically impaired and that an active site mutant, PP2Ac-H118N, causes a similar interfering effect. Only these two mutant proteins were tested for catalytic activity in vitro, but we have found that none of the PP2Acalpha dominant-negative alleles supports yeast cell growth when expressed from the PGK1 promoter (not shown) indicating that each may encode a catalytically impaired, yet largely folded protein. Consistent with this, the model of PP2Ac structure predicts that the interfering forms of HsPP2Ac either lack or disrupt key metal- or substrate-binding residues implicated in catalytic function rather than subunit interaction, and suggests further that even the truncated mutant forms retain a properly folded portion of the molecule capable of binding regulatory subunits. In this respect it may be significant that N-terminal sequences of both PP1 and PPV are implicated in recognizing regulatory subunits (25). Furthermore, the interfering effect of our HsPP2Ac mutant proteins is similar to that caused by a mutant form of fission yeast PP2Ac, containing a substitution equivalent to R239Q in HsPP2Ac, that inhibits cell growth in a dosage-dependent fashion (39). An equivalent substitution in the fission yeast PP1c causes aggregation of the mutant protein and interferes with wild type PP1c function by an unknown mechanism. This raises the possibility that HsPP2Ac-interfering proteins may be imperfectly folded and confer their inhibitory effect by forming aggregates that may trap other PP2A subunits. However, active site mutant forms of protein tyrosine phosphatases can cause an interfering effect via substrate trapping, protecting substrates from dephosphorylation by a wild type enzyme (40) suggesting that the catalytically impaired PP2Ac-L199P and PP2Ac-H118N proteins, and other interfering HsPP2Ac forms, may exert their effects by causing a similar protection of PP2Ac substrates. In this study we also generated a PP2AcDelta 67 allele in vitro encoding the N-terminal 67 amino acids of HsPP2Ac and which is similar to a mutant allele PP2Ac2202 that dominantly enhances signaling from activated Ras during Drosophila eye development (41). In our yeast system PP2AcDelta 67 did not cause a dominant-negative effect supporting the conclusion that the phenotype conferred by PP2Ac2202 in heterozygous insect cells is caused by a reduction in PP2Ac dosage and not by an intrinsic property of a truncated gene product.

The C-terminal Leucine Is Dispensable for Essential PP2Ac Function-- The invariant C-terminal leucine residue of PP2Ac is methylated by a novel transferase enzyme (22) that modulates PP2A activity and targeting (21, 42). Nevertheless, Leu-309 is dispensable for HsPP2Ac function because a mutant protein lacking this residue supported yeast cell growth in the absence of ScPP2Ac. Because methylation of PP2Ac increases catalytic activity (21), the de-methylated Leu-309 residue may perform an inhibitory role that optimizes PP2A function but is not essential under our growth conditions. Remarkably, removal of Leu-309 from HsPP2Ac was less inhibitory than the abnormal presence of alanine at this position. The reason for this is unclear but may indicate that the apparent inhibitory role of the PP2Ac C-terminal residue is less easily relieved when alanine replaces the highly conserved leucine.

Interfering Mutant Forms of Human PP2Ac Generated in Yeast-- Yeast cells functionally expressing HsPP2Ac provide a convenient system to identify inhibitory forms, facilitating both the generation of a library of PP2Acalpha mutant alleles and the rapid screening for alleles that inhibit PP2Ac function in vivo. We generated PP2Acalpha dominant-negative alleles in yeast cells lacking endogenous ScPP2Ac, but when the same alleles were tested in wild type yeast, they again inhibited cell growth, indicating an interference with ScPP2Ac. Thus, a screen for growth inhibitory forms of HsPP2Ac might have been performed in wild type cells without prior manipulation of the yeast genome, although the inhibitory effect of the PP2Acalpha mutant alleles was more dramatic when endogenous ScPP2Ac was functionally impaired. Perhaps ScPP2Ac interacts more efficiently than HsPP2Ac with endogenous yeast proteins, and unless mutationally impaired, it is less easily outcompeted by interfering forms of HsPP2Ac. Consistent with this, HsPP2Ac supported a lower rate of yeast cell growth than ScPP2Ac (Fig. 1B and not shown). Nevertheless, our results suggest that yeast might be employed to generate interfering forms of other mammalian proteins, provided there is cross-species conservation of protein function and especially if a strain containing a non-lethal mutation in the yeast orthologue is available. Here, this approach has identified residues important for HsPP2Ac function and catalytic activity. Moreover, the results of our study provide the first dominant-negative mutant forms of human PP2Ac, reagents which may be used to explore the role and regulation of PP2A in a variety of cell processes and cell types and that will therefore open up new avenues of investigation.

    ACKNOWLEDGEMENTS

We thank Mike Stark (Dundee University) for strains and plasmids; David Barford (Oxford University) for the coordinates of the PP1gamma 1 structure; Mike Hall (Biozentrum, Basel) and P. Mathijs Voorhoeve (NCI, Amsterdam, Netherlands) for plasmids; Herbert Angliker for DNA sequence analysis; and Mirjana Andjelkovic, Thomas Millward, and Linda Ireland for comments on the work.

    FOOTNOTES

* This work was supported by a Human Frontiers program grant (to B. A. H.) and a European Union Structural Biology program grant (to B. A. H.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Friedrich Miescher Institute, Maulbeerstrasse 66, CH-4058, Basel, Switzerland. Tel. 41-61-697-4872; Fax: 41-61-697-3976; E-mail: hemmings@FMI.CH.

2 T. Myles and B. A. Hemmings, manuscript in preparation.

    ABBREVIATIONS

The abbreviations used are: PP2A, protein phosphatase 2A; PP1, protein phosphatase 1; PP2Ac, PP2A catalytic subunit; 5-FOA, 5-fluoroorotic acid; HsPP2Ac, human PP2Ac; ScPP2Ac, yeast PP2Ac; HA, hemagglutinin epitope; PCR, polymerase chain reaction; PAS, protein A-Sepharose; TBS, Tris-buffered saline; ts, temperature-sensitive; kb, kilobase pair; PAGE, polyacrylamide gel electrophoresis; ORF, open reading frame.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Cohen, P. (1989) Annu. Rev. Biochem. 58, 453-508[CrossRef][Medline] [Order article via Infotrieve]
2. Barton, G. J., Cohen, P. T. W., and Barford, D. (1994) Eur. J. Biochem. 220, 225-237[Medline] [Order article via Infotrieve]
3. Barford, D., Das, A. K., and Egloff, M. P. (1998) Annu. Rev. Biophys. Biomol. Struct. 27, 133-164[CrossRef][Medline] [Order article via Infotrieve]
4. Wera, S., and Hemmings, B. A. (1995) Biochem. J. 311, 17-29
5. Evans, D. R. H., and Hemmings, B. A. (1998) Nature 394, 23-24[CrossRef][Medline] [Order article via Infotrieve]
6. Millward, T. A., Zolnierwicz, S., and Hemmings, B. A. (1999) Trends Biochem. Sci. 24, 186-191[CrossRef][Medline] [Order article via Infotrieve]
7. Mayer, R. E., Hendrix, P., Cron, P., Matthies, R., Stone, S. R., Goris, J., Merlevede, W., Hofsteenge, J., and Hemmings, B. A. (1991) Biochemistry 30, 3589-3597[CrossRef][Medline] [Order article via Infotrieve]
8. Hendrix, P., Mayer-Jaekel, R. E., Cron, P., Goris, J., Hofsteenge, J., Merlevede, and Hemmings, B. A. (1993) J. Biol. Chem. 268, 15267-15276[Abstract/Free Full Text]
9. Hendrix, P., Turowski, P., Mayer-Jaekel, R. E., Goris, J., Hofsteenge, J., Merlevede, W., and Hemmings, B. A. (1993) J. Biol. Chem. 268, 7330-7337[Abstract/Free Full Text]
10. McCright, B., and Virshup, D. M. (1995) J. Biol. Chem. 270, 26123-26128[Abstract/Free Full Text]
11. Csortos, C., Zolnierowicz, S., Bako, E., Durbin, S. D., and DePaoli-Roach, A. A. (1996) J. Biol. Chem 271, 2578-2588[Abstract/Free Full Text]
12. Mayer-Jaekel, R. E., Ohkura, H., Ferrigno, P., Andjelkovic, N., Shiomi, K., Uemura, T., Glover, D. M., and Hemmings, B. A. (1994) J. Cell Sci. 107, 2609-2616[Abstract]
13. McCright, B., Rivers, A. M., Audlin, S., and Virshup, D. M. (1996) J. Biol. Chem. 271, 22081-22089[Abstract/Free Full Text]
14. Hubbard, M. J., and Cohen, P. (1993) Trends Biochem. Sci. 18, 172-177[CrossRef][Medline] [Order article via Infotrieve]
15. Sneddon, A. A., Cohen, P. T. W., and Stark, M. J. R. (1990) EMBO J. 9, 4339-4346[Medline] [Order article via Infotrieve]
16. Ronne, H., Carlberg, M., Hu, G-Z., and Nehlin, J. O. (1991) Mol. Cell. Biol. 11, 4876-4884[Abstract/Free Full Text]
17. van Zyl, W, Huang, W., Sneddon, A. A., Stark, M., Camier, S., Werner, M., Marck, C., Sentenac, A., and Broach, J. R. (1992) Mol. Cell. Biol. 12, 4946-4959[Abstract/Free Full Text]
18. Healy, A. M., Zolnierowicz, S., Stapleton, A. E., Goebl, M., DePaoli-Roach, A. A., and Pringle, J. R. (1991) Mol. Cell. Biol. 11, 5767-5780[Abstract/Free Full Text]
19. Evangelista, C. C., Rodriguez-Torres, A. M., Limbach, M. P., and Zitomer, R. S. (1996) Genetics 142, 1083-1093[Abstract]
20. Di Como, C. J., and Arndt, K. T. (1996) Genes Dev. 10, 1904-1916[Abstract/Free Full Text]
21. Favre, B., Zolnierowicz, S., Turowski, P., and Hemmings, B. A. (1994) J. Biol. Chem. 269, 16311-16317[Abstract/Free Full Text]
22. Xie, H., and Clarke, S. (1994) J. Biol. Chem. 269, 1981-1984[Abstract/Free Full Text]
23. Xie, H., and Clarke, S. (1994) Biochem. Biophys. Res. Commun. 203, 1710-1715[CrossRef][Medline] [Order article via Infotrieve]
24. Groves, M. R., Hanlon, N., Turowski, P., Hemmings, B. A., and Barford, D. (1999) Cell 96, 99-110[CrossRef][Medline] [Order article via Infotrieve]
25. Egloff, M.-P., Cohen, P. T. W., Reinemer, P., and Barford, D. (1995) J. Mol. Biol. 254, 942-959[CrossRef][Medline] [Order article via Infotrieve]
26. Goldberg, J., Huang, H. B., Kwon, Y. G., Greengard, P., Nairn, A. C., and Kuriyan, J. (1995) Nature 376, 745-753[CrossRef][Medline] [Order article via Infotrieve]
27. Kaiser, C., Michaelis, S., and Mitchell, A. (1994) Methods in Yeast Genetics , Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
28. Brunelli, J. P., and Pall, M. L. (1993) Yeast 9, 1299-1308[CrossRef][Medline] [Order article via Infotrieve]
29. Stotz, A., and Linder, P. (1990) Gene (Amst.) 95, 91-98[CrossRef][Medline] [Order article via Infotrieve]
30. Evans, D. R. H., and Stark, M. J. R. (1997) Genetics 145, 227-241[Abstract]
31. Khew-Goodall, Y., Mayer, R. E., Maurer, F., Stone, S. R., and Hemmings, B. A. (1991) Biochemistry 30, 89-97[CrossRef][Medline] [Order article via Infotrieve]
32. Voorhoeve, P. M., Hijmans, E. M., and Bernards, R. (1999) Oncogene 18, 515-524[CrossRef][Medline] [Order article via Infotrieve]
33. Cohen, P., Schelling, D. L., and Stark, M. J. R. (1989) FEBS Lett. 250, 601-606[CrossRef][Medline] [Order article via Infotrieve]
34.